Discovery and Verification of Multi-component Chinese Medicine with Anti-tumor Activity from Shuanghuanglian
10.13422/j.cnki.syfjx.20201523
- VernacularTitle:双黄连抗结肠癌活性组分中药的发现和验证
- Author:
Pei-huang WEI
1
;
Wei ZHANG
1
;
Cheng LI
1
;
Shi-ying TAO
1
;
Cheng-ke CAI
1
;
Qiang LI
1
;
Jian LI
1
Author Information
1. Beijing University of Chinese Medicine， Beijing 100029， China
- Publication Type:Research Article
- Keywords:
Shuanghuanglian;
multi-component Chinese medicine （MCCM）;
anti-tumor;
colon cancer
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2020;26(15):69-74
- CountryChina
- Language:Chinese
-
Abstract:
Objective:The methods of network pharmacology were adopted to predict Multi-component Chinese Medicine （MCCM） with anti-tumor activity from Shuanghuanglian （SHL）. Furthermore， the pharmaceutical activity of CT26 colon cancer was verified in vitro and in vivo. Method:Based on the Traditional Chinese Medicine Systems Pharmacology Database （TCMSP）， the Handbook of Active Components Analysis of Traditional Chinese Medicine， the Drugbank database， the Reactome database， and the Human protein reference database （HPRD）， the protein-protein interactions network （PPI） and the drug target network were built and resolved. The data was mined to discover the pharmacological effect. The anti- tumor activity of components from SHL was determined based on the nearest distance rule between the compounds and the nodes of network. And then， the anti-tumor effect of the MCCM was verified in vitro and in vivo. Result:The 3 combined compounds， baicalin， forsythoside A and chlorogenic acid with the anti-tumor activity from SHL were predicted and discovered. The verification results showed that the combination of baicalin-forsythoside A-chlorogenic acid could significantly inhibit the cell proliferation and migration compared with the control group in vitro （P<0.01）. Among CT26 bearing mice， the tumor volume and weight were significantly decreased after the combined administration of baicalin-forsythoside A-chlorogenic acid compared with the model group in vivo （P<0.01）. Conclusion:By the methods of network pharmacology， the anti-tumor activities of component of from SHL were discovered. According to the verification in vitro and in vivo， the combination of baicalin-forsythoside A-chlorogenic acid could play better anti-CT26 tumor activity.
